Objective: To examine treatment practices in cases where selective serotonin reuptake inhibitors (SSRIs) 
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sants (TCAs) or monoamine oxidase inhibitors (MAOIs), have significantly improved the available treatment options for depression. Despite the increasing number of marketed antidepressants, between 19% and 34% of patients with depression still do not respond to acute antidepressant treatment, 29% to 46% may fail to achieve and sustain a full remission (I), and between 15% and 50% will have a recurrence of depression despite continuous antidepressant treatment (2) .
Determining how to proceed when faced with a case of partial response or nonresponse to an SSRI remains a major challenge in psychopharmacology. When a first-line treatment for depression fails (particularly in cases ofpartial or incomplete response, or in the case of those who respond but lose benefit), clinicians often choose to increase the dosage or augment with a second agent prior to considering switching agents altogether (3) . Combining an SSRI with other agents such as TCAs or lithium is a popular strategy (4) . There is, however, limited literature comparing the use of augmentation strategies for treatment of depression in controlled or blinded trials (3) . Some commonly used antidepressantaugmenting agents that have received support in the literature include lithium and triiodothyronine (T 3 ) (3) (4) (5) (6) (7) (8) , pindolol (9-11), buspirone (12) (13) (14) (15) (16) , bupropion (17) , and central nervous system (CNS) stimulants (18) , although the evidence for the last 4 agents is largely preliminary.
The relative lack of clinical research data has required psychiatrists to develop their own methods for managing patients with refractory depression. In the absence of adequate research data, reviewing the experience of clinicians who practice psychopharmacology in various settings can be a useful means of evaluating the management of patients who do not respond to an SSRI. Some researchers have tried to synthesize treatment preference by this approach. For example, Shergill and Katona surveyed 300 British psychiatrists who were presented with a vignette involving a case of refractory depression initially treated with a TCA (19) . The predominant approach of those surveyed was either to increase the dosage ofthe TCA or to change to an SSRI. Conversely, augmenting with T 3 , tryptophan, or MAOIs were infrequently used treatment options. Lithium was chosen by only 12% of the respondents, despite its reputation as a preferred augmenting agent.
Using a similar vignette, Nierenberg surveyed 118 psychiatrists in the northeastern US (20) . In this survey, lithium augmentation was chosen by more than one-third of the respondents. Augmenting with thyroid hormone or bupropion were each chosen by 1 respondent. Switching agents was not a preferred treatment option. Byrne and Rothschild surveyed psychiatrists' management of recurring depression in patients on maintenance therapy with SSRIs or nortriptyline (21) . Rather than switching or augmenting, most psychiatrists in this survey preferred to increase the dose of antidepressant, particularly when SSRIs were used.
In a recent study, we examined augmentation strategies among 20 Harvard faculty psychiatrists at the Outpatient Psychiatry Department of Massachusetts General Hospital (MGH) (22) . Based on perceived effectiveness and tolerability, bupropion, methylphenidate, and dextroamphetamine were the preferred agents for SSRI augmentation. Bupropion is structurally related to amphetamine, which may account at least in part for its effectiveness, particularly when it is noted that, as previously mentioned, CNS stimulants have been shown in case series to be effective augmenters of SSRIs in individuals with depression (18) . Alternative explanations may include the norepinephrine-enhancing role of bupropion. Lithium was a rarely preferred augmentation agent among our faculty, although a plethora of reports in psychiatric literature indicate that it is considered by many to be first line (3) (4) (5) (6) (7) (8) .
The disparity in treatment options may reflect either differences in North American and British practices or the time frame of the study. For example, Nierenberg's study (20) took place around the time that SSRIs were first introduced to the antidepressant market, before these agents were fully established among practitioners. In any case, the varying results of these studies suggest that further comparative research regarding protocols for managing treatment-resistant depression is needed. To examine whether our clinical experiences and those reviewed here were comparable to those of other psychiatrists in general, we conducted a survey of a wide range of clinicians from different settings, geographic locations, and years in practice, examining their preferences for the management ofpatients not fully responding to treatment with an SSRI.
Method
We surveyed clinicians who attended the MGH annual psychopharmacology course from October [16] [17] [18] 1998 . The MGH course was attended by 801 clinicians (including 630 psychiatrists, 38 physicians in other specialties, and various other practitioners) from different parts of the US (Table 1) . We administered a questionnaire prior to the start of the course so that the information presented in the course would not influence the survey response.
The questionnaire first asked for basic demographic information, practice location and type, and years in practice. The next portion involved a vignette in which a fictitious patient with new-onset depression had been treated with an adequate dose of an SSRI but had responded only partially after 3 months. Participants were asked to rank, in order of preference, the following 3 general strategies for managing such a patient: 1) increasing the dose, 2) switching antidepressants, and 3) augmenting with another agent. They were then asked what class of antidepressant agent they would choose if they decided to switch the patient to a new agent. Finally, when they chose to augment or combine treatments, they were asked to list in order of preference their first 3 choices for an augmenting agent. For each of the strategies, responses were tabulated as the percentage ofclinicians choosing the strategy as their first choice. Specific antidepressants chosen were ranked in order of preference. Using Statview software, we performed a descriptive analysis using nominal frequency distribution for answers given by participants.
As a related question, it was of interest to analyze whether these treatment preferences varied by geographic location, type of practice, and number of years in practice. We performed multiple analyses of the data, correcting for these variables. Using the Massachusetts telephone-guide division ofgeographic locations, we divided the US into the following portions: Northeast, Southeast, West Coast, and Central US. Canada was assigned its own category. There were too few participants from other countries to permit a significant analysis of their particular strategies. Types of practices selected for analysis included community hospital, academic centre, group practice, and individual practice because these were the most frequently encountered in this sample. The number of years in practice was divided into 3 categories: 1) Bupropion was the most widely chosen augmenting agent among 445 respondents (30%, n = 134), followed by lithium (22%, n = 98). The 6 most commonly chosen agents are illustrated in Figure 2 .
Results
The clinicians who returned the surve y came from various clinical settings and geographic locations and included a small number of foreign physicians (Table 1) . A total of 466 clinicians (58%) who had been in practice a mean of 16.6 years (SD 10.7) returned the questionn aires. Not all clinici ans chose to answer every question on the surve y, so for indiv idual questions those who did not answer were excluded from the anal ysis. For the fictitious patient, 84% (n = 382) of 455 respondents chose to increa se the dose of the SSRI; 10% (n = 47) chose augmentation or combination; and 7% (n = 3 1) opted for switching agents. When asked to swit ch to another agent, 52% (n = 235) of 448 respondents chose a newer antidepressant, 34% (n = 152) chose another SSRI, 10% (n = 44) chose a TCA , 2% (n = 8) chose an serotonin-norepinephrine reuptake inhibitor (SNRI), 1% (n = 5) chose an MAOI, and 1% (n = 4) chose an und efmed "other" agent ( Figure 1 ).
Trends in strategies did not vary much throughout different parts of North America, and were consistent with the pattern obta ined for the clinician sample as a whole. In all parts of the US and Canada, increasing the dose was the preferred next step in management of the vignette patient (Table 2) . West Coast clinicians (n = 17), however , preferred switching to another SSRI over switching to a new antidepressant (56% for West Coast respondents compared with 33% of all other US respondents; X 2 = 3.03, stat isticall y significant at a = 0.10). Canadian clinicians (n = 19) also showed a slight preference for this strategy, although the difference was not statistically significant (37% for Canadian respondents compared with 34% for US respondents; X 2 = 1.23, ata =0.10). Canadianrespondents also included MAOIs as their third most popular "top choice" for switching agents ( 16%, n = 3). Canadian respondents overwh elmingl y preferred lithium to bupropion for augmentation (58% for Canadian respondents compared Table 2 . Choices by geographic area, demographic area, and years in practice with 20% for US respondents; statistically significant by Fisher's exact test, P = 0.0003). Other notable findings include the Canadian group's preference for pindolol (16%, n = 3) when compared with bupropion (5%, n = 1) as an augmenting agent, and the Central US group's slight preference for buspirone (16%, n = 12) when compared with lithium (15%, n = 11).
Among different types of practices, we observed no significant differences in strategies for choosing to increase the SSRI dose and choosing to switch to newer agents (Table 2) . However, individual, group, and community clinicians together tended to augment with bupropion by almost a 2 to 1 margin over lithium (35% compared with 19%), whereas academic physicians showed a slight preference for lithium over bupropion (23% compared with 18%). The difference between these 2 groups was statistically significanttj' =4.03, at a = 0.05) ( Table 2) .
Clinicians with fewer than 10 years' experience (n = 129) showed equal preference for either bupropion or lithium augmentation (25% and 26% respectively), as opposed to clinicians with more than 10 years' experience (n = 298), who favoured bupropion over lithium (33% compared with 20%) (Table 2) . This difference was statistically significant (X 2 =
3.11 at a = 0.10).
Discussion
This survey was conducted to assess the use of different strategies for the management of depression refractory to SSRI treatment. Clinicians sampled preferred increasing the dose of the SSRI as the first-line strategy for treatment of patients who show only partial improvement in response to SSRI treatment. Increasing the SSRI dose is in accordance with the American Psychiatric Association practice guidelines for the treatment of major depression (23) and is the most logical step because it is simple to do and can be done quite safely...Conversely, studies have suggested that the SSRIs have a flat dose-response relationship (24, 25) , so further investigation may be required to confirm the effectiveness ofthis strategy. Among surveyed clinicians, augmenting and switching were unpopular as a first-line choice. This is certainly consistent with the findings that increasing the dose of fluoxetine for partial responders was more effective than was adding desipramine or lithium (4).
With regard to switching to another agent, more than one-half of clinicians favoured the newer antidepressants, although a significant number favoured switching to another SSRI. Although it is not clear whether nonresponse to one SSRI predicts failure when treated with another SSRI, many clinicians may believe this to be the case, and this may influence the choice of second-line agents. Tolerability may be an issue as well, because newer antidepressants may in some cases be perceived to have an even more benign side effect profile than the SSRIs, .although the latter are also relatively benign.
When augmenting the SSRI with another agent, clinicians overwhelmingly favoured bupropion, despite the fact that the literature supports lithium or T 3 augmentation (3-8). These observations agree with our survey our own clinicians (22) . The reasons for bupropion's popularity and perceived effectiveness among clinicians may include complementarity of mechanism and positive impact on sexual dysfunction (26) .
Thus, while the literature may support the use of lithium, many patients find it unacceptable because of its significant side effect profile. To increase compliance, clinicians need to select a treatment that is both effective and acceptable to patients. Ofnote here is a recent report (27) describing 3 cases of new-onset seizures in patients who were prescribed combinations of bupropion and either fluoxetine or fluvoxamine. However, given the apparently widespread use of SSRI-bupropion combinations, these reports may not reflect drug-drug interactions per se. Finally, it is possible that the inhibition of cytochrome P4502D6 by bupropion may result in increased serum levels of SSRIs, which may contribute to its augmenting effect. Further investigation is necessary to clarify this question.
Strategies for the management of the patient in the case vignette did not significantly differ for clinicians from different parts of North America. There was, however, a tendency for Canadian clinicians to prefer lithium as an augmenting agent, and West Coast practitioners had an approximately equal preference for lithium and bupropion. All other clinicians preferred bupropion. This might reflect idiosyncratic practices, or perhaps bupropion may be more aggressively marketed in some parts of the US. Bupropion has not been marketed in Canada for as long as it has in the US, and this may also explain its relatively lower popularity in Canada. Canadian and West Coast clinicians also showed a slight preference for SSRIs as a first choice when switching agents, and, in addition, Canadian practitioners tended to use MAOIs (which are available in reversible forms in Canada) much more readily than did US practitioners. Canadian clinicians seemed also to favour pindolol for augmentation, but the small size of the Canadian cohort of the sample requires that we not overinterpret these results. Respondents from the central US showed a significant preference for buspirone as an alternative augmenting agent.
We also observed that academic physicians had a slight preference for lithium as an augmenting agent, whereas individual, group, and community clinicians preferred to augment with bupropion. This might be explained by the fact that academics are likely to be more familiar with the psychiatric literature, which, as mentioned previously, favours lithium as an augmenting agent (3) (4) (5) (6) (7) (8) . Nevertheless, the psychiatrists surveyed at MGH tended to prefer bupropion as an augmenting agent (22) . It is possible that MGH clinicians might be more apt to disregard the literature in favour ofclinical observation' or it may reflect an idiosyncratic practice of a single clinical group. In all types ofpractice, there was a trend to increase the dosage ofthe SSRI as opposed to switching or augmenting agents as a first-line therapy for a refractory patient. The same trend prevailed for switching class of agent: newer antidepressants were preferred to SSRIs, and TCAs were relatively less popular.
In terms of the influence of years in practice on medication choice, we found that more experienced clinicians preferred bupropion as an augmenter, while less experienced ones preferred lithium. Initially this seems counterintuitive: one would expect more recently trained clinicians to use newer agents, while those who have been out oftraining for a longer time might prefer agents with which they have more experience. This reverse trend could be explained as follows: a younger clinician may tend to follow the psychiatric literature emphasized during residency training, while an older clinician, on the other hand, may have a better appreciation of the limitations of older augmentation strategies such as lithium and may be more inclined to seek novel approaches. Again, this trend conforms to the experience of the MGH faculty, who, according to our survey, tended to avoid lithium as an augmenting agent (22) .
We have shown that clinicians report that they prefer to manage patients with depression who do not respond adequately to SSRIs by increasing the dose of the SSRI and that, if they choose to switch, newer agents tend to be the antidepressants of choice. In instances where augmentation is used, bupropion tends to be the overall first choice, although certain subsets of the sample population tend to favour lithium. Because the overwhelming number of participants were psychiatrists, we therefore believe that these results are an accurate reflection of how psychiatrists tend to manage patients with depression who do not respond adequately to an SSRI. To our knowledge, this is the largest survey of clinicians ever conducted that inquires about augmentation strategies. We hope that understanding treatment practices for a patient who has failed to respond to an SSRI will help evolve the algorithm for treatment-resistant patients. Surveys that are less geographically restricted should be carried out to obtain a more generalizable picture of clinicians' approachesto managing partial responders to SSRIs. Controlled studies comparing the effectiveness of bupropion with lithium and other agents as SSRI augmenters should also assist in the further development of augmentation algorithms.
